Akeso Inc. has announced results from a real-world study comparing cadonilimab plus chemotherapy to a PD-1 inhibitor plus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction cancer with PD-L1 CPS <5. The findings, presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), indicate that the cadonilimab regimen significantly improved both overall survival (median OS 14.3 months vs. 10.3 months; HR=0.49, p=0.025) and progression-free survival (median PFS 9.3 months vs. 5.8 months; HR=0.43, p=0.006) compared to the PD-1 inhibitor group. The objective response rate was also higher in the cadonilimab group (73.3% vs. 57.1%). Safety profiles were comparable between the two groups, with no significant difference in grade 3-4 adverse events. The full study has been accepted for publication in the Journal of Gastrointestinal Oncology. Akeso is also advancing prospective Phase III studies, including the COMPASSION-37 trial, which received FDA approval to initiate at the end of 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN63076) on January 14, 2026, and is solely responsible for the information contained therein.